Sanguine Biosciences – a leading biospecimen procurement services company that empowers patients to accelerate precision medicine and cell and gene therapy research and development – recently announced that it secured $10 million in credit financing from Catalio Capital Management, a leading multi-strategy healthcare and life science investment firm.
This loan is from Catalio’s Structured Opportunities Fund, which provides creative and flexible structured capital solutions to healthcare and life sciences companies.
The senior secured term loan provides Sanguine with an initial draw of $6 million at close, with an additional $4 million available at the company’s option. And Sanguine will use the funding to support its recently launched apheresis donation center, develop instrumental cell & gene therapy products derived from apheresis, including GMP-grade and CD34+ mobilized leukopaks, and fund commercial growth.
KEY QUOTES:
“Catalio is thrilled to partner with Sanguine to support its mission of empowering patients to participate in medical research and advance precision medicine. By providing a diversity of annotated and relevant biospecimens essential for clinical research, Sanguine is well-positioned to thrive in the rapidly expanding cell and gene therapy market.”
— Catalio Capital Management General Partner and Head of Credit John Henry Iucker, CFA, joins Sanguine’s board of directors as an Observer
“Our partnership with Catalio is an important step forward for Sanguine as we bridge the gap between researchers and patients, leading to advanced therapies and likely better outcomes. This financing will enable our business to continue to innovate, grow, and align with our customers’ needs.”
— Sanguine CEO Brian Neman, MHA
